台灣臨床試驗主持人資料庫|TPIDB

2017-02-01 - 2021-12-27

Phase III

Completed

A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN

Condition/Disease

Prostatic Neoplasms, Castration-Resistant
Test Drug

Atezolizumab

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

林永昌

Linkou Chang Gung Medical Foundation

2017-01-22 - 2023-12-22

Phase III

Completed

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

Condition/Disease

Ulcerative Colitis
Test Drug

Filgotinib (GS-6034) Filgotinib (GS-6034)

Participate Sites
8Sites

Terminated4Sites

Study ended1Sites

邱正堂

Linkou Chang Gung Medical Foundation

2017-01-20 - 2025-08-15

Phase III

Completed

A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)

Condition/Disease

Head and Neck Neoplasms
Test Drug

Keytruda

Participate Sites
7Sites

Terminated7Sites

王宏銘

Linkou Chang Gung Medical Foundation

楊慕華

Taipei Veterans General Hospital

Division of Radiation Therapy

2017-01-17 - 2020-09-30

Phase III

Completed

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER

Condition/Disease

Gastric Cancer,Gastroesophageal Junction Cancer
Test Drug

Nivolumab/Ipilimumab/Oxaliplatin/Fluorouracil/Leucovorin/Capecitabine

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

陳仁熙

Linkou Chang Gung Medical Foundation

洪逸平

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-01-15 - 2020-01-31

Phase I

Completed

Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, IlarisR (canakinumab) or MekinistR (trametinib)

Condition/Disease

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Test Drug

PDR001、CJM112、ACZ885/Ilaris® 、EGF816、TMT212/Mekinist®

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

侯明模

Linkou Chang Gung Medical Foundation

2017-07-15 - 2022-06-30

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

莊正鏗

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-06-15 - 2025-12-31

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated4Sites

林永昌

Linkou Chang Gung Medical Foundation

黃書彬

Kaohsiung Municipal Gangshan Hospital

未分科

2016-06-01 - 2024-06-28

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated6Sites

莊正鏗

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-12-01 - 2027-12-31

Phase II/III

Active

Condition/Disease
Test Drug

Participate Sites
4Sites

Recruiting4Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-12-01 - 2028-12-29

Phase III

Active

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated6Sites

馮思中

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

Search Result

List